• Citer

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

par Di Leo, Angelo ;Desmedt, Christine ;Bartlett, John M S;Piette, Fanny;Ejlertsen, Bent;Pritchard, Kathleen;Larsimont, Denis ;Poole, Christopher;Isola, Jorma;Earl, Helena;Mouridsen, Henning;O'Malley, Frances P;Cardoso, Fatima ;Tanner, Minna;Munro, Alison;Twelves, Chris J;Sotiriou, Christos ;Shepherd, Lois;Cameron, David A;Piccart-Gebhart, Martine ;Buyse, Marc;HER2/TOP2A Meta-analysis Study Group,
Référence Lancet oncology, 12, 12, page (1134-1142)
Publication Publié, 2011-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Auteur:	Di Leo, Angelo; Desmedt, Christine; Bartlett, John M S; Piette, Fanny; Ejlertsen, Bent; Pritchard, Kathleen; Larsimont, Denis; Poole, Christopher; Isola, Jorma; Earl, Helena; Mouridsen, Henning; O'Malley, Frances P; Cardoso, Fatima; Tanner, Minna; Munro, Alison; Twelves, Chris J; Sotiriou, Christos; Shepherd, Lois; Cameron, David A; Piccart-Gebhart, Martine; Buyse, Marc; HER2/TOP2A Meta-analysis Study Group,
Informations sur la publication:	Lancet oncology, 12, 12, page (1134-1142)
Statut de publication:	Publié, 2011-11
Sujet CREF:	Cancérologie
MeSH keywords:	Anthracyclines -- administration & dosage
	Antigens, Neoplasm -- genetics
	Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
	Breast Neoplasms -- drug therapy -- genetics -- mortality -- pathology
	Chemotherapy, Adjuvant
	Chi-Square Distribution
	Clinical Trials, Phase III as Topic
	DNA Topoisomerases, Type II -- genetics
	DNA-Binding Proteins -- genetics
	Disease-Free Survival
	Evidence-Based Medicine
	Female
	Gene Amplification
	Gene Deletion
	Humans
	In Situ Hybridization, Fluorescence
	Individualized Medicine
	Kaplan-Meier Estimate
	Middle Aged
	Patient Selection
	Predictive Value of Tests
	Proportional Hazards Models
	Randomized Controlled Trials as Topic
	Receptor, erbB-2 -- genetics
	Risk Assessment
	Risk Factors
	Survival Rate
	Time Factors
	Treatment Outcome
	Tumor Markers, Biological -- genetics
Note générale:	Journal Article
	Meta-Analysis
	Research Support, Non-U.S. Gov't
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(11)70231-5
	info:pii/S1470-2045(11)70231-5
	info:scp/81255129146
	info:pmid/21917518